Updated duration of response for patients receiving dostarlimab plus carboplatin-paclitaxel treatment compared with patients receiving placebo plus carboplatin-paclitaxel in the ENGOT-EN6-NSGO/GOG-3031/RUBY trial

Mansoor Mirza; Lyndsay Willmott; Sakari Hietanen; Lucy Gilbert; Tashanna Myers; Boglárka Balázs; Kathryn Pennington; Dirk Bauerschlag; Eirwen Miller; Ingrid Boere; Barbara Buttin; Mitchell Edelson; Jonathan Boone; Matthew Powell; John Diaz; Robert Holloway; Matthew Grimshaw; Laura Austin; Giorgio Valabrega; Joseph Buscema

doi:10.1016/j.ygyno.2025.04.079

Back

Updated duration of response for patients receiving dostarlimab plus carboplatin-paclitaxel treatment compared with patients receiving placebo plus carboplatin-paclitaxel in the ENGOT-EN6-NSGO/GOG-3031/RUBY trial

Journal article

Peer reviewed

Updated duration of response for patients receiving dostarlimab plus carboplatin-paclitaxel treatment compared with patients receiving placebo plus carboplatin-paclitaxel in the ENGOT-EN6-NSGO/GOG-3031/RUBY trial

Mansoor Mirza, Lyndsay Willmott, Sakari Hietanen, Lucy Gilbert, Tashanna Myers, Boglárka Balázs, Kathryn Pennington, Dirk Bauerschlag, Eirwen Miller, Ingrid Boere, …

Gynecologic oncology, Vol.200, p.87

09/2025

DOI: https://doi.org/10.1016/j.ygyno.2025.04.079

Metrics

9 Record Views

Details

Title: Updated duration of response for patients receiving dostarlimab plus carboplatin-paclitaxel treatment compared with patients receiving placebo plus carboplatin-paclitaxel in the ENGOT-EN6-NSGO/GOG-3031/RUBY trial
Creators: Mansoor Mirza
Lyndsay Willmott
Sakari Hietanen
Lucy Gilbert
Tashanna Myers
Boglárka Balázs
Kathryn Pennington
Dirk Bauerschlag
Eirwen Miller
Ingrid Boere
Barbara Buttin
Mitchell Edelson
Jonathan Boone
Matthew Powell
John Diaz
Robert Holloway
Matthew Grimshaw
Laura Austin
Giorgio Valabrega
Joseph Buscema
Publication Details: Gynecologic oncology, Vol.200, p.87
Identifiers: 991006226353902656
Academic Unit: Obstetrics & Gynecology
Language: English
Resource Type: Journal article

Updated duration of response for patients receiving dostarlimab plus carboplatin-paclitaxel treatment compared with patients receiving placebo plus carboplatin-paclitaxel in the ENGOT-EN6-NSGO/GOG-3031/RUBY trial

Related links

Metrics

Details